US EditionSabin Vaccine Institute's Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
More than 640 doses of the BARDA-funded cAd3-Marburg vaccine will be tested in a two-cohort Phase 2 trial to protect high-risk workers and assess vaccine safety and efficacy.
- Dec. 04, 2025, the Sabin Vaccine Institute sent more than 640 doses of its investigational cAd3‑Marburg Vaccine to Ethiopia after the Ethiopia Ministry of Health requested support for the first‑ever Marburg outbreak response.
- Ethiopia's Ministry of Health confirmed 13 Marburg virus disease infections, including eight deaths, and there are no licensed vaccines, with case fatality rates up to 88%.
- Under a clinical trial agreement, Sabin will provide investigational cAd3‑Marburg Vaccine doses for a two‑cohort Phase 2 trial, with the U.S. government approval, limited to high‑risk workers and recent contacts.
- Early trials show the vaccine is safe with rapid immune responses; more than 2,000 trial participants have received it without significant safety concerns, supported by U.S. Department of Health and Human Services and BARDA funding.
- Once rare, Marburg outbreaks have surged in Africa in recent years, and Sabin is coordinating with ReiThera, IQVIA and CEPI—the same partners that supported Rwanda's 2024 response.
14 Articles
14 Articles
CDC's Outbreak Alert; New Hair-Loss Drug; Why Patients Dump Their Doctors
(MedPage Today) -- Note that some links may require registration or subscription. Amid an outbreak of Marburg virus disease in Ethiopia, the CDC alerted U.S. doctors to be on the lookout for travel cases of the Ebola-like virus. Meanwhile, at...
Sabin Vaccine Institute's Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to support the country's response to its first-ever outbreak of Marburg virus disease. Marburg is a highly contagious hemorrhagic fever disease and can have a high case fatality rate of up to 88%. There are currently no licensed vaccines or treatments for Marburg. Soon after Marbur…
CDC releases advisory on Marburg virus outbreak in Ethiopia; ASPR to provide support
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U.S. is low. In addition, the Administration for Strategic Preparedness and Response announced Dec. 4 that it will provide up to 2,500 doses of the Sabin Vaccine Institute’s Marburg vaccine and up to 25 treatment courses of Mapp Biopharmaceutical’s monoclonal antibody therapeutic to support…
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
